Baricitinib (brand name Olumiant) belongs to a new class of medicines called ‘targeted synthetic disease modifying antirheumatic drugs’ (tsD
Tofacitinib (brand name: Xeljanz) belongs to a class of medicines called non-biological disease modifying antirheumatic drugs (non-biologica
This website has been independently developed by Arthritis Australia for Australian users. We thank our sponsors for their support for an unrestricted, educational grant to fund its creation.
© Copyright Arthritis Australia 2020 | Website by Commune Digital